Unnamed: 0,title,date,stock,sentiment
255057.0,Celsion Reports Data On Phase II Ovarian Cancer Study,2020-05-29 08:46:00-04:00,CLSN,negative
255058.0,Stocks That Hit 52-Week Highs On Tuesday,2020-05-26 10:32:00-04:00,CLSN,neutral
255059.0,71 Biggest Movers From Friday,2020-05-26 04:30:00-04:00,CLSN,neutral
255060.0,46 Stocks Moving In Friday's Mid-Day Session,2020-05-22 12:45:00-04:00,CLSN,neutral
255061.0,Stocks That Hit 52-Week Highs On Friday,2020-05-22 10:31:00-04:00,CLSN,neutral
255062.0,Mid-Morning Market Update: Markets Fall; Alibaba Earnings Beat Estimates,2020-05-22 10:12:00-04:00,CLSN,neutral
255063.0,30 Stocks Moving in Friday's Pre-Market Session,2020-05-22 07:18:00-04:00,CLSN,neutral
255064.0,Celsion shares are trading lower after the company reported worse-than-expected Q1 EPS results.,2020-05-15 08:41:00-04:00,CLSN,neutral
255065.0,Celsion Q1 EPS $(0.200) Misses $(0.170) Estimate,2020-05-15 08:03:00-04:00,CLSN,negative
255066.0,"Earnings Scheduled For May 15, 2020",2020-05-15 05:06:00-04:00,CLSN,neutral
255067.0,"Celsion Wins $2.5M In Non-Dilutive Funding From Sale Of New Jersey State Net Operating Losses, Grant Funding Under Paycheck Protection Program",2020-04-23 08:32:00-04:00,CLSN,positive
255068.0,UPDATE: Celsion Says Independent Data Monitoring Committee Expected To Meet In Jul. 2020 To Conduct Second Interim Analysis,2020-04-15 08:43:00-04:00,CLSN,neutral
255069.0,Celsion Reports Prescribed Minimum Number Of Events Of 158 Patient Deaths Has Been Reached For Second Pre-Specified Interim Analysis Of OPTIMA Phase 3 Study Of ThermoDox,2020-04-15 08:42:00-04:00,CLSN,positive
255070.0,"The Daily Biotech Pulse: FDA Nod For Bristol-Myers Squibb, Xencor Licenses Tech To Vir For COVID-19 Treatment, Delay In Pfizer's Upjohn-Mylan Merger",2020-03-26 08:23:00-04:00,CLSN,negative
255071.0,Celsion's OVATION 1 Study With GEN-1 In Ovarian Cancer Shows Strong Progression-Free Survival Treatment Effect Utilizing Medidata Synthetic Control Arm,2020-03-26 08:16:00-04:00,CLSN,negative
255072.0,"Celsion Q4 EPS $(0.77) Down From $(0.68) YoY, Sales $500K, Same YoY",2020-03-25 16:17:00-04:00,CLSN,neutral
255073.0,Celsion's GEN-1 Immunotherapy Receives Orphan Drug Designation from the European Medicines Agency,2020-03-23 08:13:00-04:00,CLSN,neutral
255074.0,Celsion Announces Initial Clinical Results From Phase I Portion Of Phase I/II OVATION 2 Study With GEN-1 In Patients With Advanced Ovarian Cancer,2020-03-19 08:03:00-04:00,CLSN,negative
255075.0,"Celsion Chair, Pres, CEO Sends Letter To Shareholders",2020-03-03 08:38:00-05:00,CLSN,neutral
255076.0,Stocks That Hit 52-Week Lows On Friday,2020-02-28 10:16:00-05:00,CLSN,negative
255077.0,Celsion Highlights PResentation Of ThermoDox Trial Data By Medical Professor At SPECTRUM 2020 Interventional Oncology Conference,2020-02-04 08:32:00-05:00,CLSN,neutral
255078.0,98 Biotechnology Stocks Moving In Wednesday's Session,2020-01-22 13:33:00-05:00,CLSN,neutral
255079.0,116 Healthcare Stocks Moving In Wednesday's Session,2020-01-22 12:37:00-05:00,CLSN,neutral
255080.0,"Week Ahead In Biotech: PDUFA Date Ahead For Astra Zeneca, Merck's Lynparza, Pending Clinical Readouts In Focus",2019-12-29 18:38:00-05:00,CLSN,neutral
255081.0,Celsion Shares Tick Slightly Higher As Hearing Co. Granted European Patent Number EP2814464 For 'Thermosensitive nanoparticle formulations and method of making the same',2019-12-18 12:03:00-05:00,CLSN,positive
255082.0,"Earnings Scheduled For November 15, 2019",2019-11-15 05:09:00-05:00,CLSN,neutral
255083.0,"Celsion Q3 EPS $(0.25) Beats $(0.28) Estimate, Sales $125K Beat $80K Estimate",2019-11-14 16:29:00-05:00,CLSN,neutral
255084.0,Celsion Offers Comment On Common Stock Purchase Deal With Aspire Capital,2019-11-14 08:15:00-05:00,CLSN,neutral
255085.0,Celsion Highlights Publication Of Research On Fluorescence Imaging Of ThermoDox Uptake In Int'l. Journal Of Hyperthermia,2019-11-14 08:15:00-05:00,CLSN,neutral
255086.0,Stocks That Hit 52-Week Lows On Wednesday,2019-11-13 10:50:00-05:00,CLSN,negative
255087.0,Stocks That Hit 52-Week Lows On Monday,2019-11-04 14:45:00-05:00,CLSN,negative
255088.0,Celsion Reports Independent Data Monitoring Committee Unanimously Voted For Recommendation To Continue Phase 3 OPTIMA Study Of ThermoDox In Primary Liver Cancer,2019-11-04 08:13:00-05:00,CLSN,negative
255089.0,"Celsion Q2 EPS $(0.29) Beats $(0.32) Estimate, Sales $125K Miss $130K Estimate",2019-08-14 16:31:00-04:00,CLSN,negative
255090.0,Celsion Highlights Publication Of Results Of NIH Analysis Of ThermoDox In Journal Of Vascular And Interventional Radiology,2019-08-13 08:16:00-04:00,CLSN,neutral
255091.0,"Celsion Highlights GEN-1 Immunotherapy In Oppenheimer's Expert Call On Ovarian Cancer Treatment Landscape, Emerging Opportunities",2019-08-09 08:34:00-04:00,CLSN,negative
255092.0,30 Healthcare Stocks Moving In Thursday's After-Market Session,2019-07-26 04:36:00-04:00,CLSN,neutral
255093.0,Celsion shares are trading higher after the company announced it received IRB approval to begin the clinical study of ThermoDox in combination with MR-HIFU.,2019-06-20 09:03:00-04:00,CLSN,positive
255094.0,Celsion Receives IRB Approval To Begin A Clinical Study Of ThermoDox Plus High Intensity Focused Ultrasound In Breast Cancer Patients At University Medical Center Utrecht In Netherlands,2019-06-20 08:33:00-04:00,CLSN,positive
255095.0,"Celsion Q1 EPS $(0.12) Beats $(0.27) Estimate, Sales $125K Miss $130K Estimate",2019-05-15 08:11:00-04:00,CLSN,negative
255096.0,Celsion Corporation Announces Issuance Of New Patent For ThermoDox,2019-04-17 08:03:00-04:00,CLSN,neutral
255097.0,55 Biggest Movers From Yesterday,2019-04-04 05:19:00-04:00,CLSN,neutral
255098.0,"Celsion Q4 EPS $(0.27) Misses $(0.14) Estimate, Sales $125K Miss $130K Estimate",2019-03-29 08:08:00-04:00,CLSN,negative
255099.0,"Earnings Scheduled For March 29, 2019",2019-03-29 04:18:00-04:00,CLSN,neutral
255100.0,Celsion Highlights Presentation Of GEN-1 Data At ASCO-SITC Clinical Immuno-Oncology Symposium,2019-03-04 08:35:00-05:00,CLSN,neutral
255101.0,54 Biggest Movers From Yesterday,2019-01-24 05:04:00-05:00,CLSN,neutral
255102.0,Celsion Announces Publication Ff ThermoDox Study Results In Radiology Journal,2019-01-17 08:33:00-05:00,CLSN,positive
255103.0,"Celsion To Present GEN-1 Data At Upcoming ASCO-SITC Clinical Immuno-Oncology Symposium On Mar. 2, 2019",2019-01-15 08:36:00-05:00,CLSN,neutral
255104.0,"Stocks Which Set New 52-Week Low Yesterday, Tues., Dec. 20, 2018",2018-12-20 11:33:00-05:00,CLSN,negative
255105.0,"The Daily Biotech Pulse: Tilray Inks Cannabis Drink Pact, Double Delight For Merck, FDA Snub For Spectrum",2018-12-20 07:53:00-05:00,CLSN,positive
255106.0,"Stocks Which Set New 52-Week Low Yesterday, Tues., Dec. 18, 2018",2018-12-19 12:43:00-05:00,CLSN,negative
255107.0,Celsion Reports Independent Data Monitoring Committee For Co.'s Pivotal Phase III OPTIMA Study Of ThermoDox In Combo With RFA For Living Cancer Unanimously Recommended Study Continue,2018-12-18 08:09:00-05:00,CLSN,negative
255108.0,Celsion Says May Offer And Sell Shares Of Co's Common Stock Having An Aggregate Offering Price Of Up To $16 Mln From Time To Time,2018-12-06 06:08:00-05:00,CLSN,positive
255109.0,Celsion Receives $11.1M Allocation Through New Jersey Technology Business Tax Certificate Transfer (NOL) Program,2018-12-03 09:17:00-05:00,CLSN,neutral
255110.0,"Stocks Which Set New 52-Week Low The Last Trading Session, Wed., Nov. 21, 2018",2018-11-23 09:09:00-05:00,CLSN,negative
255111.0,"Stocks Which Set New 52-Week Low Yesterday, Tues., Nov. 20, 2018",2018-11-21 08:50:00-05:00,CLSN,negative
255112.0,"The Daily Biotech Pulse: Mylan Recalls Blood Pressure Drug, Heat Biologics Offering, New Novelion CEO",2018-11-21 08:04:00-05:00,CLSN,negative
255113.0,"Celsion Corporation Q3 EPS $(0.26) Misses $(0.22) Estimate, Sales $125K Miss $130K Estimate",2018-11-14 16:34:00-05:00,CLSN,negative
255114.0,Celsion Announces Date From Phase I Immuno-Oncology Study In Ovarian Cancer Patients; Data Showed GEN-1 Was Tell Tolerated And That Intraperitoneal Administration Is Feasible With Broad Patient Acceptance,2018-10-24 09:27:00-04:00,CLSN,negative
255115.0,"The Week Ahead In Biotech: Conferences, PDUFA Dates, Clinical Trial Results And IPOs",2018-09-23 16:10:00-04:00,CLSN,neutral
255116.0,"The Week Ahead In Biotech (Sept. 16-22): Conferences, PDUFA Dates, Clinical Trial Results And IPOs",2018-09-16 14:22:00-04:00,CLSN,neutral
255117.0,22 Stocks Moving In Monday's Pre-Market Session,2018-09-10 08:03:00-04:00,CLSN,neutral
255118.0,"The Week Ahead In Biotech: Conferences, Clinical Trial Results, Earnings And IPOs",2018-09-09 16:46:00-04:00,CLSN,neutral
255119.0,Celsion S-3 Shows Registration For $75M Mixed Securities Shelf Offering,2018-09-07 16:39:00-04:00,CLSN,positive
255120.0,Celsion Announces First Patient Is Enrolled In OVIATION II Study,2018-09-06 08:02:00-04:00,CLSN,neutral
255122.0,Celsion Announces  Approval of Its Application to Sell Net Operating Losses for up to $10M in Non-Dilutive Funding,2018-09-04 08:33:00-04:00,CLSN,positive
255123.0,"Celsion Announces Agreement With Aspire Capital Fund For Offering Of $15M Plus 164,835 Commitment Shares",2018-09-04 08:12:00-04:00,CLSN,positive
255124.0,Celsion Says Quarterly and Year-to-Date Cash Expenses Consistent With Prior Guidance,2018-08-14 08:32:00-04:00,CLSN,neutral
255125.0,"Celsion Q2 EPS $(0.46) Up From $(0.79) YoY, Sales $125K Inline",2018-08-14 08:31:00-04:00,CLSN,neutral
255126.0,Celsion Announces Publication Of Thermodox Phase I Clinical Study Results In The Lancet Oncology Journal,2018-07-10 08:10:00-04:00,CLSN,neutral
255127.0,The Week Ahead In Biotech: Delayed Clinical Trial Releases In Focus,2018-06-30 17:32:00-04:00,CLSN,negative
255128.0,Celsion Announces a $10M Loan From Horizon Technology,2018-06-28 08:36:00-04:00,CLSN,neutral
255129.0,48 Biggest Movers From Yesterday,2018-06-20 03:55:00-04:00,CLSN,neutral
255130.0,38 Stocks Moving In Tuesday's Mid-Day Session,2018-06-19 13:44:00-04:00,CLSN,neutral
255131.0,"Celsion Q1 EPS $(0.25) Beats $(0.30) Estimate, Sales $125K Miss $130K Estimate",2018-05-11 08:00:00-04:00,CLSN,negative
255132.0,"Earnings Scheduled For May 11, 2018",2018-05-11 04:51:00-04:00,CLSN,neutral
255133.0,"Celsion CEO Michael Tardugno Buys 2,500 @ Avg Price: $2.30 -Form4",2018-04-09 13:15:00-04:00,CLSN,neutral
255134.0,"Celsion Reports FY17 EPS $(2.72) Misses $(1.13) Est., Sales $500K Inline With $500K Estimate",2018-03-27 08:37:00-04:00,CLSN,negative
255135.0,"Celsion Reports FY17 EPS $(2.72) vs $(11.89) In Prior Year Period, Sales $500K vs $500K In Prior Year Period",2018-03-27 08:31:00-04:00,CLSN,neutral
255136.0,"Earnings Scheduled For March 27, 2018",2018-03-27 05:27:00-04:00,CLSN,neutral
255137.0,"Celsion CORP: Tardugno Michael H (Director, Chairman, President and CEO) Buys 7,500 @ Avg Price: $2.38 (Form4)",2018-03-05 11:28:00-05:00,CLSN,neutral
255138.0,"Celsion Expects To Begin Enrollment Of Phase I Portion Of The OVATION II Study Of GEN-1 During First Half Of 2018 In Up to 90 Patients, Says Phase I/II Study Will Be Powered To Show A 33% Improvement In The Primary Endpoint, Progression Free Survival",2018-03-05 10:22:00-05:00,CLSN,positive
255139.0,"Celsion Offers Corporate Update, '18 Outlook",2018-01-18 08:04:00-05:00,CLSN,neutral
255140.0,Celsion Reports FDA Clearance Of OVATION II Study For Evaluation Of GEN-1 Immunotherapy To Treat Newly Diagnosed Stage III/IV Ovarian Cancer,2018-01-04 08:04:00-05:00,CLSN,negative
255141.0,30 Biggest Movers From Yesterday,2017-12-28 05:01:00-05:00,CLSN,neutral
255142.0,40 Biggest Movers From Wednesday,2017-11-24 05:50:00-05:00,CLSN,neutral
255143.0,35 Stocks Moving In Wednesday's Mid-Day Session,2017-11-22 12:25:00-05:00,CLSN,neutral
255144.0,32 Stocks Moving In Wednesday's Pre-Market Session,2017-11-22 08:05:00-05:00,CLSN,neutral
255145.0,40 Biggest Movers From Yesterday,2017-11-22 05:03:00-05:00,CLSN,neutral
255146.0,Mid-Afternoon Market Update: Dow Gains 180 Points; DSW Shares Drop On Earnings Miss,2017-11-21 14:35:00-05:00,CLSN,positive
255147.0,40 Stocks Moving In Tuesday's Mid-Day Session,2017-11-21 12:42:00-05:00,CLSN,neutral
255148.0,Mid-Day Market Update: Signet Jewelers Falls After Q3 Results; Cheetah Mobile Shares Surge,2017-11-21 12:20:00-05:00,CLSN,positive
255149.0,Mid-Morning Market Update: Markets Open Higher; Lowe's Tops Q3 Expectations,2017-11-21 10:32:00-05:00,CLSN,positive
255150.0,"Oppenheimer Initiates Coverage On Celsion with Outperform Rating, Announces $9.00 Price Target",2017-11-21 08:38:00-05:00,CLSN,neutral
255151.0,33 Stocks Moving In Tuesday's Pre-Market Session,2017-11-21 08:08:00-05:00,CLSN,neutral
255152.0,7 Stock's Moving In Monday's After-Hours Session,2017-11-20 17:18:00-05:00,CLSN,neutral
255153.0,"STAT's Adam Feurstein Tweets: 'There's an analyst named Hartaj Singh at Oppenheimer who just initiated on $CLSN and $SNSS w/ outperform ratings, $9 and $7 PTs, respectively. Poor guy. FHL.'",2017-11-20 16:17:00-05:00,CLSN,negative
255154.0,42 Stocks Moving In Tuesday's Mid-Day Session,2017-11-14 12:25:00-05:00,CLSN,neutral
255155.0,34 Stocks Moving In Tuesday's Pre-Market Session,2017-11-14 08:06:00-05:00,CLSN,neutral
255156.0,"Celsion Reports Q3 EPS $(0.70) vs $(0.56) Est., Sales $125K vs $60K Est.",2017-11-14 08:01:00-05:00,CLSN,neutral
255157.0,"UPDATE: Celsion Submitted Phase I/II Trial Protocal To FDA For 30-Day Review, Expects To Initiate Enrollment oF Phase I In 1H18, To Be 50% Enrolled By End of 2018",2017-11-13 17:23:00-05:00,CLSN,neutral
255158.0,Celsion Files Immunotherapy Clinical Protocol for the Evaluation of GEN-1 to Treat Newly Diagnosed Ovarian Cancer,2017-11-13 17:20:00-05:00,CLSN,negative
255159.0,28 Stocks Moving In Monday's Mid-Day Session,2017-11-13 12:47:00-05:00,CLSN,neutral
255160.0,50 Biggest Movers From Friday,2017-10-30 05:13:00-04:00,CLSN,neutral
255161.0,45 Stocks Moving In Friday's Mid-Day Session,2017-10-27 12:32:00-04:00,CLSN,neutral
255162.0,Celsion Offers Summary Of R&D Day Held On Oct 12: Discussed 'GEN-1 Clinical Programs in Newly Diagnosed Stage III/IV Ovarian Cancer Patients',2017-10-18 08:35:00-04:00,CLSN,negative
255163.0,20 Stocks Moving In Wednesday's Pre-Market Session,2017-10-18 08:20:00-04:00,CLSN,neutral
255164.0,38 Biggest Movers From Friday,2017-10-16 04:39:00-04:00,CLSN,neutral
255165.0,35 Stocks Moving In Friday's Mid-Day Session,2017-10-13 12:31:00-04:00,CLSN,neutral
255166.0,33 Stocks Moving In Thursday's Mid-Day Session,2017-10-12 12:40:00-04:00,CLSN,neutral
255167.0,Celsion To Hold R&D Day Today 4pm-6pm ET,2017-10-12 11:04:00-04:00,CLSN,neutral
255168.0,30 Stocks Moving In Thursday's Pre-Market Session,2017-10-12 08:03:00-04:00,CLSN,neutral
255169.0,28 Stocks Moving In Wednesday's Mid-Day Session,2017-10-11 12:19:00-04:00,CLSN,neutral
255170.0,25 Stocks Moving In Wednesday's Pre-Market Session,2017-10-11 08:22:00-04:00,CLSN,neutral
255171.0,12 Biggest Mid-Day Gainers For Tuesday,2017-10-10 12:22:00-04:00,CLSN,neutral
255172.0,25 Stocks Moving In Tuesday's Pre-Market Session,2017-10-10 08:08:00-04:00,CLSN,neutral
255173.0,Maxim Group Upgrades Celsion to Buy,2017-10-05 09:28:00-04:00,CLSN,neutral
255174.0,25 Stocks Moving In Thursday's Pre-Market Session,2017-10-05 08:05:00-04:00,CLSN,neutral
255175.0,Celsion Corporation Reports Gross Proceeds of $15.6M from the Exercise of Existing Common Stock Warrants,2017-10-04 13:57:00-04:00,CLSN,negative
255176.0,18 Biggest Mid-Day Losers For Wednesday,2017-10-04 12:38:00-04:00,CLSN,negative
255177.0,Celsion Lower In Volatile Session,2017-10-04 12:22:00-04:00,CLSN,negative
255178.0,Celsion Shares Spiking Higher As Hearing Maxim Upgraded Co. To Buy,2017-10-04 11:15:00-04:00,CLSN,positive
255179.0,25 Stocks Moving In Wednesday's Pre-Market Session,2017-10-04 08:07:00-04:00,CLSN,neutral
255180.0,"UPDATE: Celsion Highlights 'Clear Evidence of Biological Activity Including Dose Dependent Increases in Inflammatory Cytokines (IL-12, IFN-g), Decreases in VEGF Levels and No Dose Limiting Toxicities'",2017-10-03 09:05:00-04:00,CLSN,positive
255181.0,"Celsion Reports Final Clinical, Translational Research Data From OVATION Study At AACR: '100% Disease Control; 86% Objective Response Rate and 86% R0 & R1 Surgical Resection Rate in All Patients Treated in Four Dose-Escalating Cohorts'",2017-10-03 09:04:00-04:00,CLSN,neutral
255182.0,Celsion Offers Update On ThermoDox In Phase III OPTIMA Study Of Primary Liver Cancer: 'OPTIMA Study Enrollment is Approaching 70%',2017-09-27 09:03:00-04:00,CLSN,negative
255183.0,"Celsion Reports Q2 EPS $(0.79) vs $(0.74) Est., Licensing Sales $125K vs $60K Est.",2017-08-15 08:02:00-04:00,CLSN,neutral
255184.0,"Earnings Scheduled For August 15, 2017",2017-08-15 04:28:00-04:00,CLSN,neutral
255185.0,"Earnings Scheduled For August 14, 2017",2017-08-14 04:42:00-04:00,CLSN,neutral
255186.0,Celsion's Data Monitoring Committee Recommends Continuation of Phase III TermoDox Study,2017-08-07 08:09:00-04:00,CLSN,positive
255187.0,Celsion Offers Latest Translational Data From OVATION Study In Newly-Diagnosed Advanced Ovarian Cancer Patients: Patients in All Cohorts Show Convincing Evidence of IL-12 Gene Transfer and Immune System Activity,2017-08-02 08:10:00-04:00,CLSN,positive
255188.0,15 Biggest Mid-Day Losers For Thursday,2017-07-06 12:51:00-04:00,CLSN,negative
255189.0,Mid-Day Market Update: Crude Oil Up Over 2%; Egalet Shares Plummet,2017-07-06 12:12:00-04:00,CLSN,negative
255190.0,Mid-Morning Market Update: Markets Open Lower; Liberty Interactive To Acquire HSN,2017-07-06 10:15:00-04:00,CLSN,positive
255191.0,"Celsion Corporation Reports $5M Registered Direct Offering, Co. Agrees To Sell ~2.435M Shares Of Stock At Price Of $2.07/Share",2017-07-06 09:15:00-04:00,CLSN,positive
255192.0,25 Stocks Moving In Thursday's Pre-Market Session,2017-07-06 08:27:00-04:00,CLSN,neutral
255193.0,Mid-Afternoon Market Update: Crude Oil Down 3.8%; Monogram Residential Trust Shares Spike Higher,2017-07-05 14:32:00-04:00,CLSN,positive
255194.0,12 Biggest Mid-Day Gainers For Wednesday,2017-07-05 13:05:00-04:00,CLSN,neutral
255195.0,Mid-Day Market Update: NASDAQ Turns Positive; O'Reilly Shares Drop Following Disappointing Comparable Store Sales,2017-07-05 12:29:00-04:00,CLSN,positive
255196.0,Mid-Morning Market Update: Markets Drop; Vantiv To Acquire Worldpay,2017-07-05 10:19:00-04:00,CLSN,negative
255197.0,"Celsion Shares Up 31.5% On Co. Update Following Completion Of OVATION Study: Highlighted 86% Objective Response Rate In Phase IB Dose Escalating Study, 100% ORR Surgical Resection Rate",2017-07-05 08:49:00-04:00,CLSN,positive
255198.0,Celsion Gives Update Following Completion of OVATION Study,2017-07-05 08:06:00-04:00,CLSN,neutral
255199.0,13G/A Filing Shows Intracoastal Capital Reporting 1.9% Stake In Celsion,2017-06-29 17:03:00-04:00,CLSN,neutral
255200.0,12 Biggest Mid-Day Losers For Friday,2017-06-23 13:06:00-04:00,CLSN,negative
255201.0,Celsion Corporation Reports Cancellation of Registered Direct Offering,2017-06-22 15:00:00-04:00,CLSN,neutral
255202.0,Mid-Afternoon Market Update: Crude Oil Down Over 1%; Clovis Oncology Shares Spike Higher,2017-06-19 14:47:00-04:00,CLSN,negative
255203.0,10 Biggest Mid-Day Losers For Monday,2017-06-19 12:45:00-04:00,CLSN,negative
255204.0,Mid-Day Market Update: Dow Gains 100 Points; Performant Financial Shares Tumble,2017-06-19 12:10:00-04:00,CLSN,positive
255205.0,Mid-Morning Market Update: Markets Open Higher; EQT To Buy Rice Energy For $6.7B,2017-06-19 10:11:00-04:00,CLSN,positive
255206.0,Celsion Corp. To Sell ~2M Shares Of Stock or Pre-Funded Warrants At Price Of $2.75/Share,2017-06-19 09:16:00-04:00,CLSN,positive
255207.0,"Stocks To Watch For June 19, 2017",2017-06-19 07:19:00-04:00,CLSN,neutral
255208.0,Mid-Afternoon Market Update: Kroger Falls Following Amazon–Whole Foods Deal; Hornbeck Offshore Shares Spike Higher,2017-06-16 14:34:00-04:00,CLSN,positive
255209.0,12 Biggest Mid-Day Gainers For Friday,2017-06-16 12:23:00-04:00,CLSN,neutral
255210.0,Mid-Day Market Update: Celsion Jumps After Withdrawing Stock Offering; Booz Allen Shares Drop,2017-06-16 12:03:00-04:00,CLSN,neutral
255211.0,Mid-Morning Market Update: Markets Open Lower; Amazon To Buy Whole Foods For $13.7 Billion,2017-06-16 10:09:00-04:00,CLSN,negative
255212.0,22 Stocks Moving In Friday's Pre-Market Session,2017-06-16 08:28:00-04:00,CLSN,neutral
255213.0,"A Peek Into The Markets: U.S. Stock Futures Up Ahead Of Housing Starts, Consumer Sentiment Data",2017-06-16 07:43:00-04:00,CLSN,neutral
255214.0,Celsion +123% Premarket @$4.35 After Withdrawing Stock Offering,2017-06-16 07:24:00-04:00,CLSN,neutral
255215.0,Celsion Spikes Higher After Hours to $2.55,2017-06-15 16:45:00-04:00,CLSN,neutral
255216.0,Celsion Issues Release Highlighting Regain Compliance With NASDAQ Listing Requirements,2017-06-14 08:08:00-04:00,CLSN,neutral
255217.0,11 Biggest Mid-Day Losers For Tuesday,2017-06-06 12:52:00-04:00,CLSN,negative
255218.0,Celsion S-1/A Shows Offering Of 3.4M Shares,2017-06-06 12:21:00-04:00,CLSN,positive
255219.0,22 Stocks Moving In Tuesday's Pre-Market Session,2017-06-06 08:12:00-04:00,CLSN,neutral
255220.0,Celsion Reports Effecting of 1-for-14 Reverse Stock Split,2017-05-26 16:06:00-04:00,CLSN,neutral
255221.0,Celsion Says Plans to Activate 5 Additional Clinical Trial Sites in Vietnam by Q2 of 2017 for Optima Study,2017-05-12 08:03:00-04:00,CLSN,neutral
255222.0,"Celsion Corporation Reports Q1 EPS $(0.12) vs $(0.13) Est., Sales $125K vs $90k Est.",2017-05-12 08:03:00-04:00,CLSN,neutral
255223.0,"Earnings Scheduled For May 12, 2017",2017-05-12 04:37:00-04:00,CLSN,neutral
255224.0,Celsion Provides Updates Clinical Data from the OVATION Study in Newly Diagnosed Advanced Ovarian Cancer Patients,2017-05-04 09:21:00-04:00,CLSN,negative
255225.0,Celsion Reports Preclinical Results of ThermoDox for Treatment of Bladder Cancer: Higher Concentrations of Doxorubicin Accumulation and Distribution within the Bladder Wall Were Achieved,2017-04-13 08:32:00-04:00,CLSN,negative
255226.0,"Benzinga's Top Upgrades, Downgrades For April 10, 2017",2017-04-10 10:21:00-04:00,CLSN,positive
255227.0,"Rodman & Renshaw Initiates Celsion With Buy, Price Target Of $1.50/Share",2017-04-10 07:54:00-04:00,CLSN,neutral
255228.0,S-1 from Celsion Shows Registration for ~6.142M Share Common Stock Offering via Selling Holders,2017-04-05 16:42:00-04:00,CLSN,positive
255229.0,"Celsion Corporation FY16 EPS $(0.85) vs. $(0.85) Est., Sales $500k vs. $500k Est.",2017-03-16 09:00:00-04:00,CLSN,neutral
255230.0,Celsion Reports $5M Public Offering,2017-02-15 07:15:00-05:00,CLSN,neutral
255231.0,UPDATE: Celsion Says Fourth Cohort of Patients Continues to Show Clinically Meaningful Responses in the Evaluation of GEN-1 in Combo with Standard of Care,2017-01-17 08:09:00-05:00,CLSN,positive
255232.0,Celsion Reports Data from OVATION Study in Newly-Diagnosed Advanced Ovarian Cancer Patients,2017-01-17 08:09:00-05:00,CLSN,negative
255233.0,Celsion Reports $1.8M Registered Direct Offering,2016-12-20 14:45:00-05:00,CLSN,neutral
255234.0,"Celsion Corporation Announces Progress with ThermoDox, CFDA Indicates that Positive Phase III OPTIMA Data Could Support Direct Regulatory Filing in China",2016-12-16 13:30:00-05:00,CLSN,positive
255235.0,Celsion Says Will Continue Phase 1b OVATION Study As Planned Following Dosing of Final Patient,2016-12-01 08:03:00-05:00,CLSN,neutral
255236.0,Celsion Announces Data Monitoring Committee Unanimously Recommends Continuation of Phase III OPTIMA Study of ThermoDox for Primary Liver Cancer,2016-11-30 08:01:00-05:00,CLSN,negative
255237.0,UPDATE: Celsion Says 'Top Line Translational Data from First Two Cohorts Demonstrates Potential Immune Activation',2016-11-10 08:33:00-05:00,CLSN,positive
255238.0,Celsion Reports Continuing Positive Data from the OVATION Study: Third Cohort of Patients Continues to Show Clinically Meaningful Responses in the Evaluation of GEN-1,2016-11-10 08:33:00-05:00,CLSN,positive
255239.0,"Celsion Reports Q3 EPS $(0.23) vs $(0.20) Est., Licensing Sales $125K vs $130K Est.",2016-11-10 08:09:00-05:00,CLSN,neutral
255240.0,Celsion Reports Issuance of Two New US Patents for GEN-1 Immuno-Oncology Product,2016-11-04 08:07:00-04:00,CLSN,neutral
255241.0,Celsion Files For 8.8M Offering By Selling Shareholders,2016-10-31 17:24:00-04:00,CLSN,neutral
255242.0,Celsion Says 'Supportive Data for the Phase III OPTIMA Study Demonstrates the Potential for a 2 Year Overall Survival Benefit',2016-10-31 09:06:00-04:00,CLSN,positive
255243.0,Celsion Reports DSMB Review of Phase 1b OVATION Study in Ovarian Cancer,2016-09-15 08:00:00-04:00,CLSN,negative
255244.0,Celsion Reports Nidenpendent NIH Analysis Showed Treatment with ThermoDox Plus RFA Could Significantly Improve Overall Survival of Patients with Primary Liver Cancer,2016-09-12 08:01:00-04:00,CLSN,negative
255245.0,15 Biggest Mid-Day Gainers For Monday,2016-08-15 12:39:00-04:00,CLSN,neutral
255246.0,"Celsion Reports Q2 EPS $(0.19) vs $(0.21) Est., Sales $125K vs $80K Est.",2016-08-15 09:00:00-04:00,CLSN,neutral
255247.0,12 Stocks Moving In Monday's Pre-Market Session,2016-08-15 08:25:00-04:00,CLSN,neutral
255248.0,Celsion +21% Premarket @$1.45 Following Positive ThermoDox Results,2016-08-15 08:07:00-04:00,CLSN,positive
255249.0,Celsion Reports Overall Survival Treatment With ThermoDox and Optimized RFA Provided 54% Risk Improvement With P-Value Of 0.02 (Statistically Significant); Chinese Cohort Of Patients Show Clinically Meaningful Benefit,2016-08-15 08:04:00-04:00,CLSN,positive
255250.0,"Earnings Scheduled For August 15, 2016",2016-08-15 04:00:00-04:00,CLSN,neutral
255251.0,"Celsion Corporation, Zhejiang Hisun Pharmaceutical Company Sign Technology Transfer, Manufacturing and Commercial Supply Agreement for the Development of its GEN-1 Immuno-Oncology Therapy",2016-08-09 09:02:00-04:00,CLSN,positive
255252.0,Celsion Announces Positive Data from the OVATION Study,2016-07-25 08:01:00-04:00,CLSN,positive
255253.0,"Celsion Reports Data from Phase III OPTIMA Study, Experts Endorse Pivotal Study",2016-07-11 08:08:00-04:00,CLSN,positive
255254.0,Celsion To Resume Trading At 2:30pm ET,2016-06-13 14:15:00-04:00,CLSN,neutral
255255.0,Celsion Corporation Reports $6 Million Registered Direct Offering Of 4.4M Shares At $1.36/Share,2016-06-13 14:04:00-04:00,CLSN,positive
255256.0,Celsion Corp. Halted News Pending,2016-06-13 13:56:00-04:00,CLSN,neutral
255257.0,Celsion Reports Q1 EPS $(0.24) vs $(0.21) Est.,2016-05-16 08:01:00-04:00,CLSN,neutral
255258.0,"Earnings Scheduled For May 16, 2016",2016-05-16 04:30:00-04:00,CLSN,neutral
255259.0,Celsion Reports Data from First Cohort of Patients in OVATION Study,2016-05-02 08:10:00-04:00,CLSN,neutral
255260.0,Celsion Corporation Reports Enrollment of Initial Patient in the OPTIMA Study in China,2016-04-26 08:04:00-04:00,CLSN,neutral
255261.0,Celsion Preclinical GEN-1 IL-12 Studies Show 98% Reduction In Tumor Burden vs. Control,2016-04-19 08:10:00-04:00,CLSN,negative
255262.0,"Celsion Reports FY15 EPS $(1.03) vs. Prior Year Quarter $(1.38), Rev. $500k vs. Prior Year $500K",2016-03-30 08:02:00-04:00,CLSN,neutral
255263.0,"Earnings Scheduled For March 30, 2016",2016-03-30 04:03:00-04:00,CLSN,neutral
255264.0,"Celsion Reports Presentation of Preclinical Data for GEN-1 IL-12 in Combo with Avastin, Doxil at AACR Meeting",2016-03-16 16:35:00-04:00,CLSN,neutral
255265.0,Celsion Reports Issuance of Key US Patent Covering Novel TheraSilence RNA Program,2016-03-01 08:06:00-05:00,CLSN,positive
255266.0,"UPDATE: Celsion Reported Year-End Cash Position $20.1M, Down from $24.1M at the End of Q3",2016-02-12 08:05:00-05:00,CLSN,neutral
255267.0,Celsion Offers Highlights from Recent Pipeline Developments for GEN-1 Immunotherapy Program,2016-02-12 08:04:00-05:00,CLSN,neutral
255268.0,Celsion Receives CFDA Approval To Begin Phase III Optima Study In China,2015-12-16 08:01:00-05:00,CLSN,positive
255269.0,"Clesion Reports Presentation of DIGNITY Phase 1, 2 ThermoDox Data at San Antonio BCS: Local Responses Observed in 60+% of Evaluable Recurrent Chest Wall Breast Cancer Patients",2015-12-14 08:07:00-05:00,CLSN,negative
255270.0,Option Alert: $CLSN Jan $4 Call; 936 Contracts @Ask @$0.10; Ref $1.84,2015-11-17 11:33:00-05:00,CLSN,positive
255271.0,Celsion Corp. Reports Q3 EPS $(0.19) vs. Est. $(0.26),2015-11-05 08:01:00-05:00,CLSN,neutral
255272.0,Celsion Presents Data on ThermoDox plus Optimized RFA in Intermediate HCC at the 2nd Asian Conference on Tumor Ablation,2015-11-02 08:11:00-05:00,CLSN,positive
255273.0,Mid-Afternoon Market Update: Crude Oil Down 5%; SunCoke Energy Shares Dip Following Q3 Results,2015-10-12 14:52:00-04:00,CLSN,negative
255274.0,Morning Market Gainers,2015-10-12 09:43:00-04:00,CLSN,neutral
255275.0,"Celsion Reports Preclinical Data for GEN-1 IL-12 Immunotherapy in Combo with Avastin, Doxil for Ovarian Cancer: Data Shows Significant Synergistic Anti-Cancer Effects",2015-10-12 08:02:00-04:00,CLSN,negative
255276.0,Celsion Corporation Enrolls First Patient in the OVATION Study,2015-09-30 08:04:00-04:00,CLSN,neutral
255277.0,"Celsion Reports Q2 Loss of $0.27/Share vs Loss of $0.31/Share Est., Licensing Sales $125K vs Loss of $110K Est.",2015-08-10 08:05:00-04:00,CLSN,negative
255278.0,Celsion Corporation Reports Updated Overall Survival Data from HEAT Study of ThermoDox® in Primary Liver Cancer,2015-08-06 08:10:00-04:00,CLSN,negative
255279.0,Morning Market Gainers,2015-07-15 09:49:00-04:00,CLSN,neutral
255280.0,Benzinga's Top Initiations,2015-07-15 09:40:00-04:00,CLSN,positive
255281.0,"Maxim Group Initiates Coverage on Celsion at Buy, Announces $12.00 PT",2015-07-15 07:09:00-04:00,CLSN,neutral
255282.0,"Celsion Shares Rise 12% After-Hours; Nearing Initiation at BTIG With Buy, $10 PT",2015-07-13 16:21:00-04:00,CLSN,positive
255283.0,"BTIG Research Initiates Coverage on Celsion at Buy, Announces $10.00 PT",2015-07-13 16:15:00-04:00,CLSN,neutral
255284.0,Morning Market Gainers,2015-07-06 09:51:00-04:00,CLSN,neutral
255285.0,Benzinga's Top #PreMarket Gainers,2015-07-06 08:17:00-04:00,CLSN,positive
255286.0,Celsion Reports Ongoing Positive Data from Its Phase 2 DIGNITY Study in Breast Cancer,2015-07-06 08:02:00-04:00,CLSN,positive
255287.0,13G Filing from Frigate Ventures on Celsion Shows New 6.5% Stake,2015-06-05 10:42:00-04:00,CLSN,neutral
255288.0,"Celsion Presents GEN-1 Immunotherapy Phase 1b Results For Recurrent Ovarian Cancer at ASCO 2015, Observed Clinical Benefit With Highest Dosage",2015-06-01 08:05:00-04:00,CLSN,negative
255289.0,Morning Market Losers,2015-05-28 09:53:00-04:00,CLSN,negative
255290.0,Celsion Reports $8M At-The-Market Direct Registered Offering,2015-05-28 08:46:00-04:00,CLSN,neutral
255291.0,"Celsion Announces Potent, Durable Preclinical Lung Expression Data for Its Novel TheraSilence RNA Program",2015-05-21 08:03:00-04:00,CLSN,positive
255292.0,Celsion Corporation Announces ASCO 2015 GEN-1 Immunotherapy Phase 1b Results in Ovarian Cancer Presentation,2015-05-13 17:01:00-04:00,CLSN,negative
255293.0,Celsion Reports Q1 Rev. Inline vs. $125K,2015-05-12 08:07:00-04:00,CLSN,neutral
255294.0,Celsion Corp. Reports Q1 EPS $(0.35) vs. Est. $(0.33),2015-05-12 08:06:00-04:00,CLSN,neutral
255295.0,"Earnings Scheduled For May 11, 2015",2015-05-11 04:04:00-04:00,CLSN,neutral
255296.0,Celsion Expands Clinical Development Plan for GEN-1 IL-12 Immunotherapy Program in Ovarian Cancer,2015-04-29 08:03:00-04:00,CLSN,negative
255297.0,Morning Market Gainers,2015-04-15 09:43:00-04:00,CLSN,neutral
255298.0,Clesion Reports Positive Interim Data from Phase 2 DIGNITY Trial: Will Initiate Euro-DIGNITY Trial This Quarter,2015-04-15 08:03:00-04:00,CLSN,positive
255299.0,"Celsion Corp. Reports FY14 EPS $(1.38) vs. Est. $(1.42), Rev. $500k vs. Est. $120K",2015-03-12 08:03:00-04:00,CLSN,neutral
255300.0,Celsion Says Results at 2 Years Post Treatment Continue to Support Protocol For Ongoing Phase III Optima Trial,2015-02-23 08:13:00-05:00,CLSN,positive
255301.0,Celsion Announces Updated Overall Survival Data from HEAT Study of ThermoDox® in Primary Liver Cancer,2015-02-23 08:02:00-05:00,CLSN,negative
255302.0,UPDATE: Celsion Slightly Falls Back Following Treatment News,2015-02-20 13:04:00-05:00,CLSN,neutral
255303.0,Celsion Jumps On Interim Data On Cancer Drug,2015-02-20 11:45:00-05:00,CLSN,negative
255304.0,Morning Market Gainers,2015-02-20 09:46:00-05:00,CLSN,neutral
255305.0,Celsion Shares Spike Higher at Open; May be Attributed to Seeking Alpha Post,2015-02-20 09:33:00-05:00,CLSN,positive
255306.0,Celsion Corporation Presents Data for GEN-1 IL-12 Immunotherapy At Molecular Medicine TRI-Conference,2015-02-20 08:05:00-05:00,CLSN,neutral
255307.0,"Celsion Corporation, myTomorrows Partner To Introduce ThermoDox",2015-01-20 08:13:00-05:00,CLSN,neutral
255308.0,Celsion Reports Submission of DNA-Based Immunotherapy Clinical Protocol to FDA Related to Part of First-Line Treatment for Ovarian Cancer,2015-01-06 08:07:00-05:00,CLSN,negative
255309.0,Celsion Corporation Receives VHP Approval to Initiate OPTIMA Study in Europe ,2014-11-05 08:06:00-05:00,CLSN,positive
255310.0,Benzinga's Top Initiations,2014-10-30 09:50:00-04:00,CLSN,positive
255311.0,Canaccord Genuity Initiates Celsion With Buy,2014-10-30 08:30:00-04:00,CLSN,neutral
255312.0,"Canaccord Genuity Initiates Coverage on Celsion Corporation at Buy, Announces $7.00 PT",2014-10-30 06:55:00-04:00,CLSN,neutral
255313.0,Celsion Presents Preclinical Data for its TheraSilence™ Platform at the miRNA World Conference Workshop on miRNA Delivery ,2014-10-29 08:09:00-04:00,CLSN,neutral
255314.0,Celsion Presents Preclinical Data For Its TheraSilence Platform At The miRNA World Conference Workshop On miRNA Delivery,2014-10-29 08:06:00-04:00,CLSN,neutral
255315.0,S-3 Filing from Celsion Shows Registration for 3.38M Share Shelf Offering Through EGWU Inc.,2014-09-16 17:20:00-04:00,CLSN,positive
255316.0,Celsion Reports Consolidated Duke University and Celsion's DIGNITY Study Clinical Data on ThermoDox® in Recurrent Chest Wall Breast Cancer Published in the International Journal of Hyperthermia ,2014-09-04 09:09:00-04:00,CLSN,negative
255317.0,Celsion Announces Enrollment Of First Patient In Global Phase 3 OPTIMA Study Of ThermoDox ,2014-09-02 08:11:00-04:00,CLSN,neutral
255318.0," Celsion Director Martinez Buys 5,000 Shares @$3.12/Share -Form 4",2014-08-15 11:18:00-04:00,CLSN,positive
255319.0,Celsion Corporation Reports Q2 EPS of $(0.38) vs $(0.32) Est; Revenue of $125.0M vs $130.0K Est,2014-08-07 08:19:00-04:00,CLSN,neutral
255320.0,Celsion Announces Positive Results From HEAT Study,2014-07-28 08:07:00-04:00,CLSN,positive
255321.0,Morning Market Movers ,2014-07-24 09:44:00-04:00,CLSN,neutral
255322.0,Celsion Reports Positive Interim Data from Phase 2 DIGNITY Breast Cancer Study,2014-07-24 08:05:00-04:00,CLSN,positive
255323.0,"Celsion Corporation CEO Tardugno Buys 5,000 Shares @$3.20/Share -Form 4",2014-06-11 13:40:00-04:00,CLSN,positive
255324.0,"Celsion Corporation Director Martinez Jr Buys 5,000 Shares @$3.20/Share -Form 4",2014-06-11 13:30:00-04:00,CLSN,positive
255325.0,"Benzinga's M&A Chatter for Tuesday June 10, 2014",2014-06-10 17:57:00-04:00,CLSN,neutral
255326.0,"Shares of Celsion Resume Trade, Now Up 20.5%",2014-06-10 08:05:00-04:00,CLSN,positive
255327.0,PREVIEW: Celsion to Resume Trading at 8:00 AM ET,2014-06-10 07:37:00-04:00,CLSN,neutral
255328.0,"Celsion to Acquire EGEN For $14M, Up to An Additional $30.4M In Milestone Payments",2014-06-10 07:32:00-04:00,CLSN,neutral
255329.0,"Celsion Announces Will Purchase EGEN for $14M in Cash, Shares",2014-06-10 07:30:00-04:00,CLSN,positive
255330.0,Celsion Halted News Pending,2014-06-10 07:25:00-04:00,CLSN,neutral
255331.0,Celsion Gets Clearance To Start Phase 3 OPTIMA Study,2014-05-21 08:05:00-04:00,CLSN,neutral
255332.0,Celsion Corporation Reports Q1 EPS of $(0.33) vs $(0.24) Est; Revenue of $125.0K vs $130.0K Est,2014-05-08 08:26:00-04:00,CLSN,neutral
255333.0,Celsion to Present Updated Overall Survival Results from HEAT Study of ThermoDox at ECIO 2014,2014-04-24 07:14:00-04:00,CLSN,neutral
255334.0,Celsion Announces Updated Overall Survival Results from the HEAT Study of ThermoDox in Primary Liver Cancer Presented at ECIO 2014 ,2014-04-24 06:22:00-04:00,CLSN,negative
255335.0,Celsion Says Recent Analysis Indicates ThermoDox Could Significantly Improve Overall Survival,2014-04-10 08:24:00-04:00,CLSN,positive
255336.0,Celsion Corporation Reports FY EPS of $(0.95); Revenue of $500.0K,2014-03-13 08:11:00-04:00,CLSN,neutral
255337.0,"Mornings Movers for Feb. 28, 2014: CETV, OTVI, MELI, REGI, GALE Moving Higher, ELGX, DECK, MDVN, CGEN, ARNA Lowr",2014-02-28 10:40:00-05:00,CLSN,neutral
255338.0,Celsion Reports Positive Interim Data from Phase 2 DIGNITY Trial in Breast Cancer ,2014-02-27 16:19:00-05:00,CLSN,positive
255339.0,Celsion Spikes Higher; May be Attributed to Seeking Alpha Post,2014-02-13 16:43:00-05:00,CLSN,neutral
255340.0,Celsion Announces Results Support Continued Clinical Development of Thermodox in a Prospective Pivotal Phase III Study ,2014-01-27 08:02:00-05:00,CLSN,positive
255341.0,Celsion Announces $15M At-The-Market Registered Direct Offering ,2014-01-15 09:09:00-05:00,CLSN,neutral
255342.0,"Celsion Announces $15M ATM Direct Offering, Sees Net Proceeds ~$13.8M",2014-01-15 09:08:00-05:00,CLSN,neutral
255343.0,Morning Market Movers ,2013-12-13 10:02:00-05:00,CLSN,neutral
255344.0,Celsion Presents Combined Clinical Data from Two Phase I Trials ,2013-12-13 08:03:00-05:00,CLSN,neutral
255345.0,"Celsion Corporation Reports Q3 EPS of $(0.30), Up 63% YOY",2013-11-12 08:09:00-05:00,CLSN,neutral
255346.0,Celsion Reports 1-for-4.5 Reverse Stock Split,2013-10-28 18:00:00-04:00,CLSN,neutral
255347.0,"HC Wainwright Initiates Coverage on Celsion Corporation at Buy, Announces $2.25 PT",2013-09-30 09:45:00-04:00,CLSN,neutral
255348.0,"Stocks to Watch for September 9, 2013",2013-09-09 15:10:00-04:00,CLSN,neutral
255349.0,Celsion Corporation and Zhejiang Hisun Pharmaceutical Company Sign Memorandum of Understanding for Future Development of ThermoDox® and Other Liposomal Formulations ,2013-07-19 08:30:00-04:00,CLSN,neutral
255350.0,Celsion Announces Jeffrey W. Church Reappointed to CFO ,2013-07-02 08:04:00-04:00,CLSN,neutral
255351.0,Morning Market Movers ,2013-06-20 09:59:00-04:00,CLSN,neutral
255352.0,Celsion Shares Rally as Co. Announces Review of ThermoDox HEAT Study,2013-06-20 08:38:00-04:00,CLSN,positive
255353.0,Celsion Rises 22% Pre-Market on Phase 3 ThermoDox® HEAT Study Presentation,2013-06-20 08:36:00-04:00,CLSN,neutral
255354.0,Afternoon Market Losers,2013-06-17 12:29:00-04:00,CLSN,negative
255355.0,Afternoon Market Losers,2013-06-14 14:01:00-04:00,CLSN,negative
255356.0,Celsion Corporation Issues Statement Regarding Misleading Blog Entry,2013-06-12 15:43:00-04:00,CLSN,negative
255357.0,Afternoon Market Losers,2013-06-12 14:10:00-04:00,CLSN,negative
255358.0,Morning Market Losers ,2013-06-12 10:03:00-04:00,CLSN,negative
255359.0,Celsion Shares Higher; May be Attributed to Seeking Alpha Article,2013-06-03 13:57:00-04:00,CLSN,positive
255360.0,Celsion Falling; Trading Lower on $9.83M Direct Offering,2013-05-31 10:24:00-04:00,CLSN,negative
255361.0,Celsion Prices 6.26M Shares at $1.57/Share ,2013-05-31 10:09:00-04:00,CLSN,positive
255362.0,Celsion Spikes Lower,2013-05-31 10:05:00-04:00,CLSN,negative
255363.0,"Shares of Celsion Continuing Sharply Higher as Co. Shows Study Data on ThermoDox Showing Meaningful PFS, Survival Benefits; Stock Now Up 75% Over Last Six Sessions",2013-05-30 12:53:00-04:00,CLSN,positive
255364.0,Afternoon Market Gainers,2013-05-29 15:01:00-04:00,CLSN,neutral
255365.0,Celsion Shares Moving Higher as Traders Cheer Findings from ThermoDox HEAT Study,2013-05-17 08:22:00-04:00,CLSN,positive
255366.0,"Celsion Shares Rally as Co. Hires Cantor Fitzgerald to Evaluate Purchase Alternatives, Study Shows Thermodox Improves PFS with Optimized Heating",2013-04-23 09:15:00-04:00,CLSN,positive
255367.0,Stocks Hitting 52-Week Lows,2013-04-18 11:13:00-04:00,CLSN,negative
255368.0,Celsion Corporation Reports FY EPS of $(0.76) vs $(0.72) Est,2013-03-18 08:06:00-04:00,CLSN,neutral
255369.0,"Earnings Scheduled For March 18, 2013",2013-03-18 04:09:00-04:00,CLSN,neutral
255370.0,Morning Market Movers,2013-02-11 10:08:00-05:00,CLSN,neutral
255371.0,Celsion Announces Zhejiang HISUN Pharmaceutical does Not Plan to Pursue Exclusive Option to License ThermoDox for China,2013-02-05 19:38:00-05:00,CLSN,positive
255372.0,Stocks Hitting 52-Week Lows,2013-02-04 10:19:00-05:00,CLSN,negative
255373.0,Stocks Hitting 52-Week Lows,2013-02-01 10:14:00-05:00,CLSN,negative
255374.0,"Roth Capital Downgrades Celsion Corporation to Neutral, Lowers PT to $1.70",2013-01-31 10:57:00-05:00,CLSN,negative
255375.0,Celsion Resumes Trading -81%,2013-01-31 07:31:00-05:00,CLSN,neutral
255376.0,Celsion Resumes Trading,2013-01-31 07:30:00-05:00,CLSN,neutral
255377.0,PREVIEW: Celsion Corporation to Resume Trading at 7:30 AM ET,2013-01-31 07:17:00-05:00,CLSN,neutral
255378.0,"Celsion Halted Wednesday, Says Will Host Conference Call Jan 31",2013-01-30 16:43:00-05:00,CLSN,neutral
255379.0,Celsion Says Heat Study Receives Fast Track Designation from FDA,2013-01-30 16:08:00-05:00,CLSN,neutral
255380.0,Celsion Halted News Pending,2013-01-30 16:03:00-05:00,CLSN,neutral
255381.0,"Brean Capital Downgrades Celsion Corporation to Sell, Lowers PT to $1.00",2013-01-17 07:56:00-05:00,CLSN,negative
255382.0,Ceslsion Resumes Trading,2013-01-16 13:41:00-05:00,CLSN,neutral
255383.0,Celsion Gap Down May be Attributed to Seeking Alpha Article,2013-01-16 13:40:00-05:00,CLSN,neutral
255384.0,Celsion Halted on Circuit Breaker,2013-01-16 13:36:00-05:00,CLSN,neutral
255385.0,Celsion Spikes Higher,2013-01-14 10:38:00-05:00,CLSN,neutral
255386.0,Stocks Hitting 52-Week Highs,2012-12-12 10:17:00-05:00,CLSN,neutral
255387.0,Celsion Shares Push Over $8 Following Disclosure of Director Buy of 14K Shares on Dec. 10th,2012-12-11 13:36:00-05:00,CLSN,positive
255388.0,UPDATE: Dawson James Initiates Celsion at Market Outperform on Phase III Catalyst  ,2012-11-27 14:02:00-05:00,CLSN,neutral
255389.0,"Dawson James Initiates Coverage Celsionoration at Market Outperform, Announces PT of $9",2012-11-27 06:37:00-05:00,CLSN,neutral
255390.0,Celsionoration Reports Q3 EPS $-0.18 vs $-0.17 Est,2012-11-12 08:08:00-05:00,CLSN,neutral
255391.0,Celsion Corp Says Continuing Phase 2 Study,2012-10-01 08:19:00-04:00,CLSN,neutral
255392.0,Celsion Thermodox Gets Orphan Drug Status in US/Europe,2012-09-14 08:07:00-04:00,CLSN,neutral
255393.0,Celsionoration Reports Q2 EPS $-0.18 vs $-0.19 Est,2012-08-14 08:08:00-04:00,CLSN,neutral
255394.0,Celsion Files $75M Mixed Securities Shelf,2012-08-13 17:16:00-04:00,CLSN,positive
255395.0,"Option Alert: Celsion October 2.5 Put; Block Trade: 3,805 Contracts @$0.20; Currently $3.13",2012-08-08 11:40:00-04:00,CLSN,negative
255396.0,Celsion Corporation Announces $10 Million Loan Facility  ,2012-06-28 08:02:00-04:00,CLSN,neutral
255397.0,"Option Alert: Celsion Call Volume at 2,303% of Average; Currently 3.01",2012-06-25 11:12:00-04:00,CLSN,positive
255398.0,"Option Alert: Celsion July 4 Call; Block Trade: 13,404 Contracts; Currently $2.95",2012-06-25 11:07:00-04:00,CLSN,negative
255399.0,Celsion CEO Says More Than One Multinational Pharmaceutical Company Has Shown Interest in Licensing Thermodox -Reuters ,2012-06-19 15:45:00-04:00,CLSN,positive
255400.0,Celsion CEO Says Chance Thermodox Could Be Approved By End of 2013 -Reuters,2012-06-19 15:44:00-04:00,CLSN,positive
255401.0,"Option Alert: Celsion Put Volume at 1,067% of Average; Currently $2.25",2012-06-07 09:50:00-04:00,CLSN,positive
255402.0,Celsion Announces Collaboration With the University of Oxford for First Ever Clinical Trial Using a Targeted Chemotherapeutic Drug Released by Ultrasound to Treat Cancer,2012-06-07 08:11:00-04:00,CLSN,negative
255403.0,Option Alert: Celsion Put Volume at 932% of Average; Currently $1.94,2012-05-30 14:29:00-04:00,CLSN,positive
255404.0,Celsion Announces Completion of Enrollment in Its Pivotal Phase III HEAT Study of ThermoDox(R) in Primary Liver Cancer  ,2012-05-30 08:02:00-04:00,CLSN,negative
255405.0,"UPDATE: Celsion, Philips Expect To Initiate Clinical Study Following FDA Acceptance",2012-05-14 10:20:00-04:00,CLSN,positive
255406.0,Celsion Announces Resubmission With Philips Healthcare of Combined IND/IDE Application for a Phase 2 Study of ThermoDox(R) and MR-Guided HIFU in Bone Cancer  ,2012-05-14 10:19:00-04:00,CLSN,negative
255407.0,Celsion Announces ThermoDox Commercial Supply Agreement With Hisun  ,2012-05-07 08:42:00-04:00,CLSN,positive
255408.0,Option Alert: Celsion Put Volume at 948% of Average ($2.06),2012-04-26 12:54:00-04:00,CLSN,positive
255409.0,Celsion Announces Data Monitoring Committee Unanimously Recommends Continuation of Phase III HEAT Study of ThermoDox,2012-04-23 08:02:00-04:00,CLSN,positive
255410.0,"Brean Murray Carret & Co. Initiates Coverage on Celsionoration at Buy, Announces PT of $7",2012-02-16 06:31:00-05:00,CLSN,neutral
255411.0,Celsion Announces First Patient Enrolled in Phase II Study of ThermoDox(R) in Combination With RFA in Colorectal Liver Metastases  ,2012-02-13 08:02:00-05:00,CLSN,neutral
255412.0,"Option Alert: Celsion July 1.5 Call; Block Trade, 2,950 Contracts",2012-01-23 15:29:00-05:00,CLSN,negative
255413.0,Notable Put Options Activity on Celsion,2011-12-28 10:04:00-05:00,CLSN,neutral
255414.0,Rodman & Renshaw Maintains Outperform on Celsion ,2011-12-20 12:21:00-05:00,CLSN,neutral
255415.0,Celsion Completes Consultative Review Process With EMA for Phase III HEAT Study of ThermoDox in Primary Liver Cancer  ,2011-12-19 09:52:00-05:00,CLSN,negative
255416.0,Notable Call Options Activity in Celsion,2011-12-01 10:38:00-05:00,CLSN,neutral
255417.0,Celsion Corporation to Raise $15 Million in Private Placement,2011-12-01 09:32:00-05:00,CLSN,neutral
255418.0,Celsion Announces Unanimous Recommendation by Independent Data Monitoring Committee to Continue and Complete Phase III HEAT Study of ThermoDox in Primary Liver Cancer as Planned  ,2011-11-28 08:01:00-05:00,CLSN,negative
255419.0,"Rodman & Renshaw Reiterates Outperform, $6 PT on Celsion Corp ",2011-11-14 08:50:00-05:00,CLSN,neutral
255420.0,Celsion Spiking Higher on Heavy Volume,2011-11-04 15:54:00-04:00,CLSN,neutral
255421.0,Celsion's Technical Breakout Appears to Have Upcoming News Wings,2011-11-01 00:54:00-04:00,CLSN,neutral
255422.0,Rodman & Renshaw Initiates Coverage on Celsion With an Outperform Rating,2011-10-26 08:10:00-04:00,CLSN,neutral
255423.0,"Rodman & Renshaw Initiates Celsion Corporation at Market Outperform, $6 PT",2011-10-26 07:45:00-04:00,CLSN,neutral
255424.0,Notable Call Options Activity in Celsion,2011-10-12 12:34:00-04:00,CLSN,neutral
255425.0,Notable Put Options Activity in Celsion,2011-09-28 11:51:00-04:00,CLSN,neutral
255426.0,Celsion Presenting Now at Rodman and Renshaw Healthcare Conference,2011-09-12 15:01:00-04:00,CLSN,neutral
255427.0,Notable Call Options Activity in Celsion,2011-09-06 12:55:00-04:00,CLSN,neutral
255428.0,Celsion Scream Higher; Breaks Through Resistance ,2011-08-29 14:54:00-04:00,CLSN,negative
255429.0,Celsion Announces Approval of $1.2M New Jersey Economic Development Authority Incentive Grant  ,2011-08-18 09:35:00-04:00,CLSN,positive
255430.0,Celsion Announces Publication of Clinical and Scientific Review of ThermoDox as Treatment for Primary Liver Cancer  ,2011-08-17 08:03:00-04:00,CLSN,negative
255431.0,Celsion Corp Violently Falling on Heavy Volume,2011-08-04 09:51:00-04:00,CLSN,negative
255432.0,Celsion Reaches Major Milestone With Enrollment of 600th Patient in Its Pivotal Phase III HEAT Study of ThermoDox in Primary Liver Cancer  ,2011-08-03 08:09:00-04:00,CLSN,negative
255433.0,Celsion Corporation Announces $18.4 Million in Financing ,2011-07-21 08:36:00-04:00,CLSN,neutral
255434.0,Unconfirmed Rumors Circulate that Phase III Results of Stimuvax Endpoint Results May Have Been Leaked,2011-07-20 08:54:00-04:00,CLSN,negative
255435.0,"Oncothyreon Gaps Higher Pre-Market Following Celsion, Cancer Sector Rally ",2011-07-20 08:42:00-04:00,CLSN,negative
255436.0,Stocks to Watch for Wednesday 7/20/2011: Fresh 52 Week Highs and Lows,2011-07-20 01:51:00-04:00,CLSN,positive
255437.0,Stocks to Watch for Thursday 7/14/2011: Fresh 52 Week Highs and Lows,2011-07-14 02:29:00-04:00,CLSN,positive
255438.0,Celsion Appoints Gregory Weaver as CFO,2011-07-12 08:09:00-04:00,CLSN,neutral
255439.0,Celsion Racing Toward Daily Highs,2011-07-07 10:39:00-04:00,CLSN,neutral
255440.0,Options Brief: Celsion Corporation,2011-07-01 10:25:00-04:00,CLSN,neutral
255441.0,Celsion Corporation Announces $6.6 Million Registered Direct Offering,2011-07-01 08:00:00-04:00,CLSN,neutral
255442.0,Options Brief: Celsion Corporation,2011-06-10 11:49:00-04:00,CLSN,neutral
255443.0,Options Brief: Celsion Corporation,2011-06-01 10:13:00-04:00,CLSN,neutral
255444.0,Options Brief: Celsion Corporation,2011-05-27 10:16:00-04:00,CLSN,neutral
255445.0,Celsion Corporation Announces $8.6M Equity Offering of Common Stock and Warrants  ,2011-05-27 08:01:00-04:00,CLSN,neutral
255446.0,"Top Percentage Gainers and Losers as of 12pm 5/13/11 (ABIO, DDS, GFRE, APL, VRML, DF, SWSH, CLSN, AERL, CA, NVDA, QTWW, IMRS, FFHL, MPG, GENE)",2011-05-13 12:04:00-04:00,CLSN,negative
255447.0,Celsion Corporation Regains Compliance With NASDAQ Listing Requirements (CLSN),2011-05-11 08:03:00-04:00,CLSN,neutral
255448.0,Options Brief: Celsion Corporation (CLSN),2011-04-26 11:53:00-04:00,CLSN,neutral
255449.0,"Celsion Corporation to Host Year-End 2010 Earnings Call and Webcast on Friday, March 25, 2011  ",2011-03-18 07:35:00-04:00,CLSN,neutral
255450.0,Celsion Corporation Announces Completion of $5.1 Million Registered Direct Offering,2011-01-21 15:42:00-05:00,CLSN,neutral
255451.0,Celsion Corporation Announces Convertible Preferred Stock Financing and Amended License Agreement for Aggregate Gross Proceeds of up to $9 Million,2011-01-13 08:00:00-05:00,CLSN,neutral
255452.0,Celsion Reports Third Quarter EPS of $(0.38),2010-11-15 14:03:00-05:00,CLSN,neutral
255453.0,Celsion Awarded Therapeutic Discovery Project Grant From US Government,2010-11-02 16:50:00-04:00,CLSN,positive
255454.0,Celsion Receives Positive FDA Guidance for its New Drug Application,2010-10-04 07:47:00-04:00,CLSN,positive
255455.0,Data Monitoring Committee Unanimously Recommends Continuation of Celsion's Phase III ThermoDox® HEAT Study ,2010-09-30 10:48:00-04:00,CLSN,positive
255456.0,Celsion Receives SBIR Grant (CLSN),2010-09-02 14:19:00-04:00,CLSN,positive
255457.0,7-13-10 The Small Cap Market Update from Express IR,2010-07-13 16:53:00-04:00,CLSN,neutral
255458.0,"Stocks That Have Crossed 52-Week Highs (ARBA, CACH, CKEC, CLSN, DISCB)",2010-04-16 15:10:00-04:00,CLSN,neutral
255459.0,"Benzinga’s Pre-market Gainers (ARGN, NTGR, OPEN, LIOX, CLSN)",2010-02-11 08:02:00-05:00,CLSN,neutral
255460.0,"Biggest Losers (XRX,FRP,CLSN,CRXL,QTWW)",2009-09-28 12:31:00-04:00,CLSN,negative
